Physician profile
David Ross Freeman
NPI 1770581142
$2,347.10
in general payments reported to CMS, 2019-2025
34 companies · $22.98 in 2025
The $22.98 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $655 · 2020: $291 · 2021: $192 · 2022: $423 · 2023: $559 · 2024: $204 · 2025: $22.98.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $786.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $786.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $630.32 | 2019-2025 | |
| Novo Nordisk INC | $236.72 | 2019-2024 | Wegovy |
| Viiv Healthcare Company | $220.22 | 2019-2023 | Apretude |
| Abbvie INC. | $199.68 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $126.64 | 2019-2021 | |
| Pfizer INC. | $120.84 | 2019-2023 | |
| Glaxosmithkline, LLC. | $87.11 | 2019-2020 | |
| Corium, LLC | $53.65 | 2022-2023 | Azstarys |
| Sanofi Pasteur INC. | $52.95 | 2019-2021 | |
| Antares Pharma, INC. | $45.31 | 2019-2023 | Tlando, Xyosted, Nocdurna |
| Organon LLC | $44.13 | 2023 | Nexplanon |
| Nestle Healthcare Nutrition INC. | $43.87 | 2023 | |
| Halozyme INC | $43.05 | 2023 | |
| Integra Lifesciences Corporation | $36.00 | 2023 | Integra, Surgimend, Omnigraft |
| Abbott Laboratories | $35.94 | 2023-2024 | Freestyle Libre 2, Freestyle Libre 3 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $30.16 | 2019 | |
| Dynavax Technologies Corporation | $28.66 | 2023 | Heplisav-B |
| Novartis Pharmaceuticals Corporation | $27.78 | 2019-2021 | |
| Amgen INC. | $26.70 | 2019 | |
| Neurocrine Biosciences, INC. | $25.33 | 2021 | |
| Seqirus USA INC | $24.20 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $23.37 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $19.76 | 2022 | |
| Xeris Pharmaceuticals, INC. | $19.67 | 2022 | |
| Axsome Therapeutics, INC. | $19.60 | 2023 | Auvelity |
| Exact Sciences Corporation | $17.89 | 2024 | Cologuard Collection Kit |
| Mylan Institutional INC. | $15.29 | 2019 | |
| Alkermes, INC. | $14.75 | 2022 | |
| Janssen Pharmaceuticals, INC | $14.04 | 2019 | |
| Neuronetics, INC. | $13.22 | 2022 | |
| Hologic Sales and Service, LLC | $13.14 | 2022 | |
| Allergan, INC. | $13.06 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $12.53 | 2021 | |
| Endo Pharmaceuticals INC. | $11.52 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Freeman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.